Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Spruce Biosciences Inc (SPRB)

Spruce Biosciences Inc (SPRB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 70,956
  • Shares Outstanding, K 1,070
  • Annual Sales, $ 4,910 K
  • Annual Income, $ -53,040 K
  • EBIT $ -49 M
  • EBITDA $ -49 M
  • 60-Month Beta 3.52
  • Price/Sales 55.21
  • Price/Cash Flow N/A
  • Price/Book 7.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -13.48
  • Number of Estimates 2
  • High Estimate -12.00
  • Low Estimate -14.95
  • Prior Year -42.86
  • Growth Rate Est. (year over year) +68.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
66.08 +0.31%
on 02/13/26
87.40 -24.15%
on 01/22/26
-15.21 (-18.66%)
since 01/13/26
3-Month
66.08 +0.31%
on 02/13/26
127.90 -48.17%
on 11/19/25
-46.28 (-41.11%)
since 11/13/25
52-Week
4.28 +1,450.64%
on 04/29/25
240.00 -72.38%
on 10/07/25
+35.53 (+115.47%)
since 02/13/25

Most Recent Stories

More News
Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)

Treatment with Weekly TA-ERT Demonstrated Rapid and Durable Normalization of Cerebral Spinal Fluid Heparan Sulfate Non-Reducing End (CSF HS-NRE), a Surrogate Endpoint Reasonably Likely to Predict Clinical...

SPRB : 66.29 (-20.09%)
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team

Daven Mody, Pharm.D., Appointed as Senior Vice President, Regulatory and Quality Bruno Gagnon, B.Pharm., M.Sc., Appointed as Senior Vice President, Clinical Development...

SPRB : 66.29 (-20.09%)
Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposiumâ„¢

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical...

SPRB : 66.29 (-20.09%)
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of...

SPRB : 66.29 (-20.09%)
Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital

Initial Funding of $15 Million from the First of Four Tranches, Extending Cash Runway into 2027 Facility Will Support Advancement and Potential Launch of TA-ERT for the...

SPRB : 66.29 (-20.09%)
Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors

Keli Walbert brings decades of commercial leadership experience and a proven track record of successful product launches in rare disease

SPRB : 66.29 (-20.09%)
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Granted Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for the Treatment of Sanfillipo Syndrome Type B (MPS IIIB) Biologics...

SPRB : 66.29 (-20.09%)
Spruce Biosciences Secures $50 Million Investment Deal

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Spruce Biosciences...

SPRB : 66.29 (-20.09%)
Spruce Biosciences Announces $50.0 Million Private Placement Financing

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical...

SPRB : 66.29 (-20.09%)
Why This Microcap Biotech Stock Surged 1,378% in a Single Day

Shares of Spruce Biosciences (NASDAQ: SPRB) surged 1,378% to $130.40 on Monday after the U.S. Food and Drug Administration granted Breakthrough Therapy Designation (BTD) to tralesinidase alfa (TA-ERT)...

SPRB : 66.29 (-20.09%)

Business Summary

Spruce Biosciences Inc. is a biopharmaceutical company. It focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy which are in clinical stage. Spruce Biosciences Inc. is based in Daly City, California.

See More

Key Turning Points

3rd Resistance Point 95.31
2nd Resistance Point 89.43
1st Resistance Point 77.86
Last Price 66.29
1st Support Level 60.40
2nd Support Level 54.52
3rd Support Level 42.95

See More

52-Week High 240.00
Fibonacci 61.8% 149.95
Fibonacci 50% 122.14
Fibonacci 38.2% 94.32
Last Price 66.29
52-Week Low 4.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar